Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NEVANAC

« Back to Dashboard
Nevanac is a drug marketed by Alcon Pharms Ltd and is included in one NDA. It is available from two suppliers. There are three patents protecting this drug.

The generic ingredient in NEVANAC is nepafenac. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.

Summary for Tradename: NEVANAC

Suppliers: see list2

Pharmacology for Tradename: NEVANAC

Clinical Trials for: NEVANAC

Efficacy Study of Triamcinolone Associated With Nepafenac for Treatment of Diabetic Macular Edema
Status: Active, not recruiting Condition: Diabetic Macular Edema

A Clinical Safety and Efficacy Comparison of NEVANAC 0.1% to Vehicle After Cataract Surgery in Diabetic Retinopathy Patients
Status: Completed Condition: Macular Edema

Nepafenac 0.3% Two Study
Status: Completed Condition: Cataract

Confirmatory Study Nepafenac 0.3%
Status: Completed Condition: Cataract

Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Status: Completed Condition: Inflammation; Pseudophakia

Effect of Topical Nepafenac in Macular Thickening Related to Pan-Retinal Photocoagulation
Status: Recruiting Condition: Macular Thickening; Macular Edema

Effect of Nepafenac Eye Drops on Intraocular Pressure in Normal Eyes
Status: Completed Condition: Intraocular Pressure

Evaluation of Comfort With Xibrom (Bromfenac Ophthalmic Solution)0.09% and Nevanac (Nepafenac Ophthalmic Suspension) 0.1% Following Selective Laser Trabeculoplasty (SLT)
Status: Completed Condition: Intraocular Pressure

A Comparison of Prostaglandin E2 (PGE2) Inhibition of Acuvail(Ketorolac 0.45%), Xibrom (Bromfenac 0.09%)and Nevanac (Nepafenac)in Patients Undergoing Phacoemulsification
Status: Completed Condition: Cataracts

Macular Edema Incidence/Severity Reduction With Nevanac
Status: Terminated Condition: Diabetic Retinopathy

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon Pharms Ltd
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes7,834,059<disabled><disabled>
Alcon Pharms Ltd
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes8,071,648<disabled>Y<disabled>
Alcon Pharms Ltd
SUSPENSION/DROPS;OPHTHALMIC021862-001Aug 19, 2005RXYes8,324,281<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn